儿童体外连续流心室辅助装置的资源利用分析
该研究合并PediMACS与PHIS数据库,分析2012至2016年19家中心177例儿童VAD植入的资源利用。PCF VAD或PCF-DVAD患儿更年幼、先心病比例更高,术后住院时间与费用显著增高,费用主要驱动因素为术前病情、住院时长和临床服务成本。
要点
- PCF VAD或PCF-DVAD患儿年龄更小、先心病比例更高。
- PCF VAD术后中位住院43天,费用中位45万美元。
- 费用驱动因素包括住院时长、术前ECMO和主要不良事件。
核心结论
- 儿童PCF VAD资源利用极高,费用主要驱动于术前病情、住院时长和临床服务成本。
研究设计与样本
- 合并PediMACS与PHIS数据库,评估2012至2016年19家中心177例儿童VAD植入。
主要发现
- 177例中PCF VAD占20%,PCF-DVAD占14%,DVAD占66%。
- PCF VAD组中位年龄4岁(IQR 0-10),PCF-DVAD组3岁(IQR 0-9),DVAD组11岁(IQR 3-17)。
- PCF VAD组先心病比例44%,PCF-DVAD组28%,DVAD组14%(p<0.01)。
- 术后中位住院时长PCF VAD为43天(IQR 15-82),PCF-DVAD为72天(IQR 55-107)。
- 住院费用中位PCF VAD为45万美元(IQR 21万-78万),PCF-DVAD为77万美元(IQR 51万-100万)。
关键数值与推荐
- 调整患者因素后,术后住院费用更高与住院时长、术前ECMO、更多慢性复杂疾病和主要不良事件相关(p<0.05)。
- VAD策略和基础心脏病与住院时长或总费用无关,但PCF VAD与更高的日均费用相关,由药房、实验室、影像和临床服务成本增加驱动。
临床怎么用
- 临床决策需考虑PCF VAD资源利用极高,尤其对年幼和先心病患儿。
- 优化术前病情、缩短住院时长可能降低费用。
局限性
- 研究为回顾性数据库合并分析,仅纳入19家中心2012至2016年数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Paracorporeal continuous-flow ventricular assist devices (PCF VAD) are increasingly used in pediatrics, yet PCF VAD resource utilization has not been reported to date. METHODS: Pediatric Interagency Registry for Mechanically Assisted Circulatory Support (PediMACS), a national registry of VADs in children, and Pediatric Health Information System (PHIS), an administrative database of children's hospitals, were merged to assess VAD implants from 19 centers between 2012 and 2016. Resource utilization, including hospital and intensive care unit length of stay (LOS), and costs are analyzed for PCF VAD, durable VAD (DVAD), and combined PCF-DVAD support. RESULTS: Of 177 children (20% PCF VAD, 14% PCF-DVAD, 66% DVAD), those with PCF VAD or PCF-DVAD are younger (median age 4 [IQR 0-10] years and 3 [IQR 0-9] years, respectively) and more often have congenital heart disease (44%; 28%, respectively) compared to DVAD (11 [IQR 3-17] years; 14% CHD); p < 0.01 for both. Median post-VAD LOS is prolonged ranging from 43 (IQR 15-82) days in PCF VAD to 72 (IQR 55-107) days in PCF-DVAD, with significant hospitalization costs (PCF VAD $450,000 [IQR $210,000-$780,000]; PCF-DVAD $770,000 [IQR $510,000-$1,000,000]). After adjusting for patient-level factors, greater post-VAD hospital costs are associated with LOS, ECMO pre-VAD, greater chronic complex conditions, and major adverse events (p < 0.05 for all). VAD strategy and underlying cardiac disease are not associated with LOS or overall costs, although PCF VAD is associated with higher daily-level costs driven by increased pharmacy, laboratory, imaging, and clinical services costs. CONCLUSION: Pediatric PCF VAD resource utilization is staggeringly high with costs primarily driven by pre-implantation patient illness, hospital LOS, and clinical care costs.
引用
- Burstein DS, Griffis H, Zhang X, et al. Resource utilization in children with paracorporeal continuous-flow ventricular assist devices. J Heart Lung Transplant. 2021. PMID: 33744087. doi:10.1016/j.healun.2021.02.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。